Elanco Animal Health Incorporated (ELAN) Q2 2025 Earnings Call Transcript
Elanco Animal Health Incorporated (NYSE:ELAN) Q2 2025 Earnings Conference Call August 7, 2025 9:00 AM ET
Company Participants
Jeffrey N. Simmons – President, CEO & Director
Robert M. VanHimbergen – Executive VP & CFO
Tiffany Kanaga – Corporate Participant
Conference Call Participants
Andrea Regina Zayco Narvaez Alfonso – UBS Investment Bank, Research Division
Daniel Christopher Clark – Leerink Partners LLC, Research Division
Ekaterina V. Knyazkova – JPMorgan Chase & Co, Research Division
Erin Elizabeth Wilson Wright – Morgan Stanley, Research Division
Jonathan David Block – Stifel, Nicolaus & Company, Incorporated, Research Division
Michael Gennaro DiFiore – Evercore ISI Institutional Equities, Research Division
Michael Leonidovich Ryskin – BofA Securities, Research Division
Navann Ty Dietschi – BNP Paribas Exane, Research Division
Operator
Ladies and gentlemen, thank you for standing by. Welcome to Elanco Animal Health Second Quarter 2025 Earnings Conference Call. [Operator Instructions] I would now like to hand the call over to Tiffany Kanaga, Head of Investor Relations. You may begin your conference.
Tiffany Kanaga
Good morning. Thank you for joining us for Elanco Animal Health’s Second Quarter 2025 Earnings Call. I’m Tiffany Kanaga, Vice President of Investor Relations and ESG. Joining me on today’s call are Jeff Simmons, our President and Chief Executive Officer; Bob VanHimbergen, our Chief Financial Officer; and Beth Haney from Investor Relations. The slides referenced during this call are available on the Investor Relations section of elanco.com. Today’s discussion will include forward-looking statements. These statements are based on our current assumptions and expectations and are subject to risks and uncertainties that could cause actual results to differ materially from our forecast. For more information, see the risk factors discussed in today’s earnings press release as well as in our latest Form 10-K and 10-Q filed with the SEC. We do not undertake any duty to update any forward-looking statements.
